Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 181 institutions reported holding it in 13F filings for Q3 2026, worth $1.08B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $577.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $222.0K in total
- 2
- 13F holdersQ3 2026, +2 vs. previous quarter
- 181
- 13F valueReported value at the end of Q3 2026
- $1.08B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$219.9M
- No comparable prior period
- Free cash flow, FY2025
- -$175.8M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 7.93M
- Shares sold short
- Change
- +288.7K
- +3.8% vs. previous
- Days to cover
- 13.33
- At average daily volume
Superinvestors holding CGEM, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding CGEM at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Cullinan Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 (view filing)5:00 PM ET | Nov 5 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −4.00K | $12.36 | −$49.4K | −2.5%158.6K after | 10b5-1 |
| Sep 10, 2026 (view filing)9:22 AM ET | Sep 8 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $21.57 | −$172.6K | −4.8%158.8K after | 10b5-1 |
| Aug 14, 2026 (view filing)5:00 PM ET | Aug 13 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −30.0K | $20.26 | −$607.8K | −15.6%162.8K after | 10b5-1 |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 6 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $17.82 | −$142.6K | −4.7%162.8K after | 10b5-1 |
| May 6, 2026 (view filing) | May 5 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $14.62 | −$117.0K | −4.6%166.8K after | 2 lots10b5-1 |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $15.68 | −$125.4K | −4.5%170.8K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 25 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −1.78K | $14.14 | −$25.2K | −1.0%174.8K after | 10b5-1 |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −5.35K | $14.31 | −$76.6K | −2.9%176.6K after | 2 lots10b5-1 |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Ahmed NadimPresident and CEO | SSale | −13.5K | $14.47 | −$195.6K | −3.3%390.8K after | |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Jones Jeffrey AlanChief Medical Officer | SSale | −4.58K | $14.47 | −$66.3K | −2.8%160.0K after |
Top 10 13F holders, Q3 2026
See all 181 holdersThe largest institutional positions in Cullinan Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MPM Oncology Impact Management LP | 9,721,081 | $149.2M | 11.49% | −10,260−0.1% | Reduced |
| Lynx1 Capital Management LP | 8,963,500 | $137.6M | 21.30% | 00.0% | Unchanged |
| BVF Inc | 5,750,683 | $88.3M | 2.90% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,319,313 | $81.7M | 0.00% | +86,547+1.7% | Added |
| Price T Rowe Associates Inc | 4,091,640 | $62.8M | 0.01% | +265,690+6.9% | Added |
| Kynam Capital Management, LP | 3,114,132 | $47.8M | 2.65% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,641,522 | $40.5M | 0.00% | +27,456+1.1% | Added |
| State Street Corp | 2,604,105 | $40.0M | 0.00% | −1,064,522−29.0% | Reduced |
| RTW Investments, LP | 2,364,347 | $36.3M | 0.37% | 00.0% | Unchanged |
| Siren, L.L.C. | 1,793,410 | $27.5M | 0.65% | −100,000−5.3% | Reduced |
Holders of 5% or more of CGEM
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Cullinan Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 13G/A | 9.99%6.49M shares | 0.00 ppfrom 9.99% | Nov 8, 20219 filings | Aug 14, 2026 | SEC |
| Lynx1 Capital Management LP | 13G/A | 9.80%5.77M shares | −4.70 ppfrom 14.50% | Aug 14, 20253 filings | Nov 14, 2025 | SEC |
| Price T Rowe Associates Inc | 13G | 6.20%3.83M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Kynam Capital Management, LP | 13G | 5.27%3.11M shares | New | Mar 4, 20261 filing | Mar 4, 2026 | SEC |